.png){kind=logo}
FDA’s FY2027 Medical Device Guidance Agenda: What Could It Mean for 510(k) Manufacturers?
The U.S. Food and Drug Administration (FDA), through its Center for Devices and Radiological Health (CDRH), has released its proposed guidance agenda for Fiscal Year 2027.
While the agenda does not establish new legal or regulatory requirements, it provides an important view into the topics CDRH intends to prioritize for guidance development and publication.
For medical device manufacturers planning U.S. submissions, particularly 510(k), AI-enabled software, and novel device projects, the agenda is worth watching closely.
A Shift Toward AI, Lifecycle Management and Evidence
The FY2027 A-list includes several notable topics.
Among them are:
Marketing Submission and Lifecycle Management Recommendations for AI-Enabled Device Software Functions
Predetermined Change Control Plans for Medical Devices
Quality Management System Information for Certain Premarket Application Reviews
Robotically-Assisted Surgical Devices – Premarket Submissions
ASCA program guidance
Menstrual products performance testing and labeling
CDRH also lists a draft guidance addressing Generative AI-Enabled Conversational Devices for Mental Disorders.
Together, these topics reflect an FDA regulatory environment increasingly focused not only on the initial safety and performance of a device, but also on software lifecycle management, planned changes, evidence, quality systems, and emerging technologies.
The 510(k) Program Deserves Particular Attention
For manufacturers using the 510(k) pathway, the most interesting signals may come from CDRH’s Under Construction list.
Two planned guidance topics are particularly significant:
Considerations for Selecting a Predicate Device to Support a 510(k) Submission
and
Select Updates for the 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]
Predicate selection and substantial equivalence are foundational elements of the 510(k) pathway.
FDA has already been examining ways to modernize this process. In 2023, the agency issued a draft guidance on best practices for predicate selection, including considerations related to the predicate’s safety history, performance, design-related issues, and recalls. FDA stated that the draft was intended to improve predictability, consistency, and transparency in the 510(k) program.
The FY2027 agenda suggests that this work remains an active area of regulatory development.
This Does Not Mean the 510(k) Rules Have Changed
This distinction is important.
The FY2027 guidance agenda is not itself a new regulatory requirement. The predicate-selection and substantial-equivalence topics currently listed under Under Construction are not new standards that manufacturers must immediately implement.
FDA guidance documents generally describe the agency’s current thinking and are not legally binding.
Therefore, manufacturers should not automatically revise an ongoing submission simply because these topics appear on the FY2027 agenda.
Instead, the appropriate response is regulatory monitoring and risk assessment.
Who Should Be Watching?
The developments may be particularly relevant to:
Medical device manufacturers planning a 510(k)
Companies developing AI-enabled devices or SaMD
Software-heavy medical device manufacturers
Surgical robotics companies
Developers of novel devices
Companies with submissions extending into 2027 and beyond
For these projects, regulatory planning may benefit from monitoring five interconnected areas:
Predicate Selection↓Substantial Equivalence↓AI Lifecycle / PCCP↓QMS Information↓Premarket Evidence
The significance is not that every project will be affected in the same way.
Rather, these developments provide insight into the areas where FDA thinking may continue to evolve.
What Should Manufacturers Do Now?
For most companies, there is no reason to immediately change an active regulatory strategy solely because the FY2027 agenda has been published.
A more practical approach is to:
1. Identify projects that extend into 2027 or later.Determine which submissions could overlap with guidance that is expected to be finalized or developed during that period.
2. Review predicate strategy for future 510(k)s.For projects still in development, document why the selected predicate is appropriate and how substantial equivalence will be supported.
3. Monitor AI and software-related developments.For AI-enabled devices, lifecycle management and PCCP developments may become increasingly relevant to both submission planning and postmarket change strategies.
4. Watch the relationship between QMS and premarket evidence.The planned QMS guidance may be particularly relevant to manufacturers preparing submissions where quality-system information becomes an important part of the review.
5. Avoid treating proposed guidance as finalized requirements.Regulatory planning should distinguish between current requirements, draft guidance, proposed guidance topics, and finalized FDA recommendations.
The Bigger Picture
CDRH's FY2027 agenda is best viewed as a regulatory roadmap rather than a rulebook.
Not every guidance topic listed by FDA will necessarily be issued exactly as currently described. CDRH notes that priorities may change and that guidance topics may be modified or removed depending on resources, public feedback, emerging issues, and other priorities.
Nevertheless, the direction is meaningful.
AI-enabled devices, lifecycle management, PCCP, QMS, predicate selection, and substantial equivalence are all areas where manufacturers may want to maintain active regulatory intelligence.
For companies planning a U.S. medical device submission in 2027 and beyond, the best time to monitor regulatory direction is before the submission is finalized—not after expectations have changed.
For inquiries or expert assistance, please contact us today.
CONTACT US
Office: 1-909-493-3276
Email: ask@provisionfda.com